Guideline

SASCM guideline for daptomycin use in South Africa – 2017 update

Warren Lowman, Jennifer Coetzee, Olga Perovic
Southern African Journal of Infectious Diseases | Vol 32, No 2 | a58 | DOI: https://doi.org/10.4102/sajid.v32i2.58 | © 2019 Warren Lowman, Jennifer Coetzee, Olga Perovic | This work is licensed under CC Attribution 4.0
Submitted: 14 May 2019 | Published: 01 July 2017

About the author(s)

Warren Lowman, Vermaak and Partners Pathologists, Pretoria, South Africa; Ampath, National Reference Laboratory, Microbiology, Pretoria, South Africa;Department of Clinical Microbiology and Infectious Diseases, University of Witwatersrand, Johannesburg, South Africa
Jennifer Coetzee, Ampath, National Reference Laboratory, Microbiology, Pretoria, South Africa
Olga Perovic, National Institute for Communicable Diseases, Centre for Tropical, Opportunistic and Hospital Infections, Johannesburg, South Africa; Department of Clinical Microbiology and Infectious Diseases, University of Witwatersrand, Johannesburg, South Africa

Full Text:

PDF (205KB)

Share this article

Bookmark and Share

Abstract

Daptomycin is currently registered for use in treatment of complicated skin and skin structure infections (cSSSI) and Staphylococcus aureus bacteraemia. The role of daptomycin in treatment of severe Gram-positive infections needs to be considered outside of these specific and rigid indications. Based on surveillance data, supporting literature and within the context of antimicrobial stewardship, the South African Society for Clinical Microbiology (SASCM) provides recommendations for appropriate use of daptomycin. These recommendations were formulated by members of the National Antimicrobial Committee (NAC), a
sub-committee of SASCM, following consultation and review of the relevant literature.


Keywords

antimicrobial stewardship; antimicrobial therapy; daptomycin; Gram-positive infections

Metrics

Total abstract views: 897
Total article views: 434


Crossref Citations

No related citations found.